Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors

Travis, Lois B.; Fosså, Sophie D.; Schonfeld, Sara J.; McMaster, Mary L.; Lynch, Charles F.; Storm, Hans H.; Hall, Per; Holowaty, Eric J.; Andersen, Aage; Pukkala, Eero; Andersson, Michael; Kaijser, Magnus; Gospodarowicz, Mary K.; Joensuu, Timo; Cohen, R.J.; Boice, John D.; Dores, Graça M.; Gilbert, Ethel S.

doi:10.1093/jnci/dji278

Cited by 753 publications

(375 citation statements)

References 58 publications

Supporting

Mentioning

336

Contrasting

Unclassified

Order By: Relevance

“…These should be considered for prolonged, at least 10-years, follow-up. Thereafter, annual routine check-ups may be arranged in conjunction with general practitioners with regard to late relapses, second cancers, and treatment-induced metabolic changes (Vaughn et al, 2002;Sagstuen et al, 2005;Travis et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

Late recurrences of germ cell malignancies: a population-based experience over three decades

et al. 2006

View full text Add to dashboard Cite

The purpose of this study was to explore the incidence of late relapse in patients with malignant germ cell tumour (MGCT) in a population-based series, with emphasis on the mode of detection, survival, and the relevance of histological findings. The clinical records from a population-based cohort of patients with seminoma (n ¼ 1123) or non-seminoma (n ¼ 826) were evaluated for late relapses. Twenty-five patients developed a late relapse. The cumulative 10-year incidence rate was 1.3%. All 10 seminoma patients, but only eight of 15 non-seminoma patients relapsed with vital malignant tumour (P ¼ 0.02). Teratoma or necrosis was found in seven of nine primarily chemotherapy-treated non-seminoma patients with normal tumour markers at late relapse. Six of nine patients operated with limited retroperitoneal lymph node dissection as part of the primary treatment had relapsed retroperitoneally outside the original operation field. The 10-year cause-specific survival was 68% in all patients, 50% in patients relapsing with vital malignant tumour and 100% in those with teratoma/ necrosis before or after salvage chemotherapy. The 10-year incidence rate of late relapses of 1.3% might reflect the true incidence rate in a population-based cohort of MGCT patients, with cure in at least half of them.

show abstract

Section: Discussionmentioning

confidence: 99%

Late recurrences of germ cell malignancies: a population-based experience over three decades

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The disadvantage of adjuvant treatment in high-risk patients is that half of the patients who receive adjuvant BEP would not have required chemotherapy at all and may be unnecessarily exposed to the side effects of chemotherapy [51][52][53][54][55], a possible transient decrease in fertility [56] and possibly a small risk of secondary malignancies, as reported from patients receiving higher doses of chemotherapy [57].…”

Section: Chemotherapymentioning

confidence: 99%

Current Concepts in Management of Stage I NSGCT

Ahluwalia

Gautam

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

While about 50% of non-seminomatous germ cell tumors of the testes present as clinical stage I (CSI), further management of these patients continues to be mired in controversy. Active surveillance is a frontline option for low-risk CS I patients and according to some, even the high-risk ones with high embryonal carcinoma (ECA) component and vascular invasion (VI). However, it carries the disadvantage of long-term surveillance, the need for prolonged chemotherapy in case of recurrence and the possibility of secondary malignancies due to radiation exposure from frequent CT scans. One or two cycles of BEP chemotherapy is a popular alternative to active surveillance which carries a very low relapse rate, but valid concerns about overtreatment of a majority of patients, with the attendant chemotherapy-related toxicity exist. Retroperitoneal lymph node dissection has been used as a means of avoiding chemotherapy, especially in high-risk patients, but carries the disadvantage of a high surgical morbidity and complications. As with any major surgical procedure, the best results are dependent on the experience and skill of the individual surgeon.

show abstract

“…VAISHALI SANCHORAWALA, 1,2* ANTHONY C. SHELTON, 1 JEROME B. ZELDIS, 3 AND DAVID C. SELDIN 1,2 Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma…”

Section: Acknowledgmentsmentioning

confidence: 99%

“…To the Editor: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare distinct subtype of HL, generally characterized by a more indolent behavior than classical Hodgkin lymphoma (cHL), male preponderance, and a median age at diagnosis of 30-40 years [1]. A recent large population-based study [2] reported that first-degree relatives of patients with NLPHL have a 19-fold risk of developing this disease, a 5.3-fold risk of cHL, and 1.9-fold risk of non-HL.…”

Section: Acknowledgmentsmentioning

confidence: 99%

See 1 more Smart Citation

Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide

Sanchorawala

Shelton

Zeldis³

et al. 2013

American J Hematol

View full text Add to dashboard Cite

Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors

Cited by 753 publications

References 58 publications

Late recurrences of germ cell malignancies: a population-based experience over three decades

Late recurrences of germ cell malignancies: a population-based experience over three decades

Current Concepts in Management of Stage I NSGCT

Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide

Contact Info

Product

Resources

About